Physician profile
David A Clark
NPI 1619952421
$2,992.87
in general payments reported to CMS, 2019-2025
18 companies · $25.23 in 2025
The $25.23 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $297 · 2021: $338 · 2022: $145 · 2023: $208 · 2024: $1,328 · 2025: $25.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $916 · Food and Beverage: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $915.52 |
| Food and Beverage | $645.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $1,247.04 | 2023-2024 | Renal - Pd, Hillrom - Cardiac Ambulatory Monitor |
| Amgen INC. | $316.31 | 2019-2024 | Repatha |
| Kowa Pharmaceuticals America, INC. | $202.00 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.27 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $138.18 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $133.52 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $120.93 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $115.63 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $105.26 | 2019-2020 | |
| Esperion Therapeutics, INC. | $100.04 | 2020-2024 | Nexletol |
| Pfizer INC. | $76.80 | 2021-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $66.08 | 2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $55.88 | 2019-2021 | |
| Abbvie INC. | $43.19 | 2021 | |
| Cvrx, INC. | $37.80 | 2024 | Barostim Neo System |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $25.49 | 2023 | Merlin@Home |
| Amarin Pharma, INC. | $17.76 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.